Lexeo Therapeutics, Inc. Common Stock
LXEONASDAQHealthcare● Active
$4.23
$-0.15(-3.32%)
Market Cap$331753904
P/E Ratio—
52W High$10.99
52W Low$2.9
Lexeo Therapeutics, Inc. Common Stock (LXEO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LXEO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.25
Est. -$0.29 · +13.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
LXEO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.31 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 11, 2026 | -$0.29 | -$0.25 | +13.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 30, 2026 | -$0.32 | -$0.27 | +15.6% | — | — | — |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.48 | -$0.33 | +31.3% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.64 | -$0.60 | +6.3% | — | — | — |
| ▼ Q2 FY2025 | May 12, 2025 | -$0.80 | -$0.99 | -23.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 24, 2025 | -$0.87 | -$0.78 | +10.3% | — | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.65 | -$0.89 | -36.9% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Beat
EPS Actual
-$0.25
EPS Est.
-$0.29
EPS Surpr.
+13.8%
Revenue
—
Q1 FY2026
Mar 30, 2026Beat
EPS Actual
-$0.27
EPS Est.
-$0.32
EPS Surpr.
+15.6%
Revenue
—
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.48
EPS Surpr.
+31.3%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.60
EPS Est.
-$0.64
EPS Surpr.
+6.3%
Revenue
—
Q2 FY2025
May 12, 2025Miss
EPS Actual
-$0.99
EPS Est.
-$0.80
EPS Surpr.
-23.8%
Revenue
—
Q1 FY2025
Mar 24, 2025Beat
EPS Actual
-$0.78
EPS Est.
-$0.87
EPS Surpr.
+10.3%
Revenue
—
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.89
EPS Est.
-$0.65
EPS Surpr.
-36.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.27 | $-0.27 | $-0.27 | 2 |
| Q3 FY2027 | $-0.32 | $-0.32 | $-0.32 | 2 |
| Q2 FY2027 | $-0.31 | $-0.31 | $-0.31 | 2 |
| Q1 FY2027 | $-0.31 | $-0.31 | $-0.31 | 2 |
| Q4 FY2026 | $-0.32 | $-0.32 | $-0.32 | 4 |
| Q3 FY2026 | $-0.36 | $-0.31 | $-0.24 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 11, 2026 | +13.8% | $5.83 | $6.12 | +4.97% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +15.6% | $5.46 | $5.27 | -3.48% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +31.3% | $8.35 | $8.20 | -1.80% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +6.3% | $4.72 | $4.79 | +1.48% |
| ▼ Q2 FY2025 | May 12, 2025 | -23.8% | $2.69 | $2.63 | -2.23% |
| ▲ Q1 FY2025 | Mar 24, 2025 | +10.3% | $2.71 | $4.09 | +50.92% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -36.9% | $7.69 | $7.64 | -0.65% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +7.3% | $11.50 | $11.98 | +4.17% |
Q2 FY2026+4.97%
Report Date
May 11, 2026
EPS Beat/Miss
+13.8%
Price Before
$5.83
Price After
$6.12
Q1 FY2026-3.48%
Report Date
Mar 30, 2026
EPS Beat/Miss
+15.6%
Price Before
$5.46
Price After
$5.27
Q4 FY2025-1.80%
Report Date
Nov 5, 2025
EPS Beat/Miss
+31.3%
Price Before
$8.35
Price After
$8.20
Q3 FY2025+1.48%
Report Date
Aug 14, 2025
EPS Beat/Miss
+6.3%
Price Before
$4.72
Price After
$4.79
Q2 FY2025-2.23%
Report Date
May 12, 2025
EPS Beat/Miss
-23.8%
Price Before
$2.69
Price After
$2.63
Q1 FY2025+50.92%
Report Date
Mar 24, 2025
EPS Beat/Miss
+10.3%
Price Before
$2.71
Price After
$4.09
Q4 FY2024-0.65%
Report Date
Nov 13, 2024
EPS Beat/Miss
-36.9%
Price Before
$7.69
Price After
$7.64
Q3 FY2024+4.17%
Report Date
Aug 12, 2024
EPS Beat/Miss
+7.3%
Price Before
$11.50
Price After
$11.98
Avg Beat Reaction+9.38%
Avg Miss Reaction-1.44%
Beat Rate6 / 8 quarters
Largest Move+50.92% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LXEO ends December
Lexeo Therapeutics, Inc. Common Stock (LXEO) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.25 — beating the analyst consensus of $-0.29 by +13.8%. LXEO has beaten EPS estimates for 4 consecutive quarters. The next LXEO earnings date is expected around September 1, 2026.
Each quarter, investors track LXEO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LXEO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LXEO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LXEO earnings · 5 questionsLexeo Therapeutics, Inc. Common Stock's next earnings report is expected around September 1, 2026. LXEO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LXEO historically reports after market close (AMC).
LXEO earnings datewhen is LXEO earningsLXEO next earnings datewhen does LXEO report earningsLXEO earnings calendar
▸ Source: FMP · Lexeo Therapeutics, Inc. Common Stock SEC filings · US GAAP · Lexeo Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026